Your session is about to expire
← Back to Search
Checkpoint Inhibitor
Tadalafil + Pembrolizumab for Head and Neck Cancer
Phase 2
Recruiting
Led By Joseph Califano
Research Sponsored by University of California, San Diego
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Patients must have normal organ and marrow function
Patients (at least 18 years of age) must have recurrent or metastatic squamous cell carcinoma of the head and neck
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights
Study Summary
This trial will test a new combination therapy for advanced head and neck cancer. The goal is to see if it is safe and effective.
Who is the study for?
Adults with recurrent or metastatic head and neck squamous cell carcinoma who have not used PD-1 or PD-L1 inhibitors in this setting, nor had certain heart conditions, autoimmune diseases, severe drug allergies, organ transplants, or are pregnant. They must have a life expectancy over 12 weeks and normal organ/marrow function.Check my eligibility
What is being tested?
The trial is testing the safety and effectiveness of combining two drugs: pembrolizumab (an immunotherapy) and tadalafil (a medication originally for erectile dysfunction), to treat advanced head and neck cancer.See study design
What are the potential side effects?
Possible side effects include immune-related reactions like inflammation in various organs, fatigue, skin rash; as well as headaches, indigestion from tadalafil. Serious cardiac events could occur due to pre-existing conditions.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My organs and bone marrow are functioning normally.
Select...
I am 18 or older with recurrent or metastatic squamous cell carcinoma of the head and neck.
Select...
My cancer can be measured by tests.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 2 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Overall Survival (OS)
Rate of Dose Limiting Toxicity (DLT)
Secondary outcome measures
Adverse event rates
Progression free survival
Response measured by RECIST 1.1
Side effects data
From 2017 Phase 4 trial • 635 Patients • NCT022248469%
Viral upper respiratory tract infection
3%
Periodontitis
3%
Prostatitis
2%
Alanine aminotransferase increased
2%
Upper respiratory tract infection
2%
Abdominal pain upper
2%
Chronic gastritis
2%
Blood uric acid increased
2%
Insomnia
1%
Pharyngitis
1%
Gout
1%
Sleep disorder
1%
Rhinitis allergic
1%
Rhinitis
1%
Eczema
1%
Influenza
1%
Back pain
1%
Diabetes mellitus
1%
Enteritis
1%
Gastritis
1%
Urinary tract infection
1%
Dizziness
1%
Epistaxis
1%
Renal cyst
1%
Gastric polyps
1%
Gastrooesophageal reflux disease
1%
Nephrolithiasis
1%
Hypertension
1%
Pyrexia
1%
Large intestine polyp
1%
Abdominal distension
1%
Abdominal pain
1%
Dental caries
1%
Diarrhoea
1%
Gamma-glutamyltransferase increased
1%
Headache
1%
Cough
100%
80%
60%
40%
20%
0%
Study treatment Arm
2.5 mg/5 mg Tadalafil
5 mg Tadalafil
Trial Design
1Treatment groups
Experimental Treatment
Group I: Tadalafil and PembrolizumabExperimental Treatment2 Interventions
Tadalafil for up to 12 months and pembrolizumab for up to 24 months.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pembrolizumab
FDA approved
Tadalafil
FDA approved
Find a Location
Who is running the clinical trial?
University of California, San DiegoLead Sponsor
1,117 Previous Clinical Trials
1,520,282 Total Patients Enrolled
Joseph Califano4.711 ReviewsPrincipal Investigator - UCSD
University of California, San Diego
5Patient Review
He is an excellent doctor and surgeon. I am an anaplastic thyroid cancer patient and he saved my life.
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- My brain metastases are stable.I am not on strong immune system suppressing drugs.I haven't had a heart attack, heart surgery, or severe heart disease in the last 6 months.I have used tadalafil or similar medications daily for at least a month in the past 3 months.You are expected to live for at least 12 more weeks.I have needed quick-relief medicine for chest pain within the last 3 months.I have had a condition where my eye's optic nerve was damaged due to poor blood supply.I am currently taking a strong medication that affects liver enzymes.I have a heart condition that blocks blood flow from my heart.I am currently taking medication that stimulates guanylate cyclase.I've had low blood pressure, blindness, or hearing loss from tadalafil or similar drugs.My organs and bone marrow are functioning normally.I have had an organ transplant.I have not had a stroke in the last 6 months.I am currently using long-acting PDE5 inhibitors.I take medication for chest pain.I haven't had chemotherapy in the last 28 days or monoclonal antibody treatment in the last 8 weeks.I have not had unstable chest pain in the last 90 days.I have a family history of retinal disorders like retinitis pigmentosa.I have not had a heart attack or uncontrolled heart issues in the last 3 months.I am currently taking nitrates for my condition.I am 18 or older with recurrent or metastatic squamous cell carcinoma of the head and neck.You have a health condition where your immune system attacks your own body.I have been treated with PD-1 or PD-L1 inhibitors for recurrent or metastatic cancer.I had a positive heart stress test without any effective heart treatment afterwards.I have a history of HIV or active hepatitis B or C.My cancer can be measured by tests.
Research Study Groups:
This trial has the following groups:- Group 1: Tadalafil and Pembrolizumab
Awards:
This trial has 3 awards, including:- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Approved for 5 Other Conditions - This treatment demonstrated efficacy for 5 other conditions.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger